glycine has been researched along with Chronic Primary Open Angle Glaucoma in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Most adverse events (AEs) were mild, and no serious treatment-related AEs were reported." | 3.01 | Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. ( Aihara, M; Iwata, A; Kawata, H; Lu, F; Odani-Kawabata, N, 2021) |
| " However, adverse events (AEs) were higher in the BID arm; thus, QD dosing is the preferred dosing frequency for further investigation." | 3.01 | A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6). ( Abrams, MA; Chabi, A; Dinh, P; Jerkins, GW; Lu, F; Odani-Kawabata, N; Olander, KW; Sato, MA; Shams, NK, 2021) |
| "Patients with glaucoma and ocular hypertension (OH) with no previous history of OMDI use were enrolled." | 1.72 | Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan. ( Kuwayama, Y; Nakazawa, T; Nomura, A; Shimada, F; Takahashi, K, 2022) |
| " The main outcome measures were the change in intraocular pressure (IOP) at week 4 and week 12 after the initiation of OMDI treatment, and frequency of adverse drug reactions." | 1.72 | Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan. ( Hori, K; Ishida, N; Miki, A; Miyamoto, E; Shii, D, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 7 (77.78) | 2.80 |
| Authors | Studies |
|---|---|
| Aihara, M | 4 |
| Lu, F | 5 |
| Kawata, H | 4 |
| Iwata, A | 4 |
| Odani-Kawabata, N | 5 |
| Inoue, K | 1 |
| Shiokawa, M | 1 |
| Katakura, S | 1 |
| Tsuruoka, M | 1 |
| Kunimatsu-Sanuki, S | 1 |
| Shimizu, K | 1 |
| Ishida, K | 1 |
| Tomita, G | 1 |
| Nakazawa, T | 1 |
| Takahashi, K | 1 |
| Kuwayama, Y | 1 |
| Nomura, A | 1 |
| Shimada, F | 1 |
| Miki, A | 1 |
| Miyamoto, E | 1 |
| Ishida, N | 1 |
| Shii, D | 1 |
| Hori, K | 1 |
| Shams, NK | 3 |
| Ropo, A | 1 |
| Shams, N | 1 |
| Olander, KW | 1 |
| Sato, MA | 1 |
| Abrams, MA | 1 |
| Jerkins, GW | 1 |
| Dinh, P | 1 |
| Chabi, A | 1 |
| Liu, K | 1 |
| Mabuchi, F | 1 |
| Yamagata, Z | 1 |
| Kashiwagi, K | 1 |
| Ishijima, K | 1 |
| Tang, S | 1 |
| Iijima, H | 1 |
| Tsukahara, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study[NCT02822729] | Phase 3 | 125 participants (Actual) | Interventional | 2016-07-01 | Completed | ||
| A Phase II/III Randomized, Double-masked, Controlled, Parallel Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-[NCT02623738] | Phase 2/Phase 3 | 253 participants (Actual) | Interventional | 2015-12-06 | Completed | ||
| A Phase III, Open-label, Single-arm, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Who Are Non-/Low-responders to Latanoprost Ophthalmic Solution: FUJ[NCT02822742] | Phase 3 | 26 participants (Actual) | Interventional | 2016-07-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for glycine and Chronic Primary Open Angle Glaucoma
| Article | Year |
|---|---|
Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
Topics: Antihypertensive Agents; Double-Blind Method; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pre | 2021 |
Periocular Adverse Reactions to Omidenepag Isopropyl.
Topics: Antihypertensive Agents; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pressure; Ocular Hyperte | 2022 |
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
Topics: Dose-Response Relationship, Drug; Female; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pressur | 2020 |
Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Topics: Administration, Ophthalmic; Aged; Antihypertensive Agents; Female; Glaucoma, Open-Angle; Glycine; Hu | 2020 |
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
Topics: Antihypertensive Agents; Double-Blind Method; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pre | 2021 |
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Topics: Aged; Antihypertensive Agents; Corneal Pachymetry; Dose-Response Relationship, Drug; Double-Blind Me | 2019 |
3 other studies available for glycine and Chronic Primary Open Angle Glaucoma
| Article | Year |
|---|---|
Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
Topics: Antihypertensive Agents; Glaucoma; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pressure; Japa | 2022 |
Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
Topics: Antihypertensive Agents; Drug-Related Side Effects and Adverse Reactions; Glaucoma; Glaucoma, Open-A | 2022 |
A sequence change (Arg158Gln) in the leucine zipper-like motif region of the MYOC/TIGR protein.
Topics: Adult; Aged; Amino Acid Motifs; Amino Acid Substitution; Arginine; Cytoskeletal Proteins; Eye Protei | 2001 |